Bayer AG
XETRA:BAYN

Watchlist Manager
Bayer AG Logo
Bayer AG
XETRA:BAYN
Watchlist
Price: 21.03 EUR 0.36% Market Closed
Market Cap: 20.7B EUR
Have any thoughts about
Bayer AG?
Write Note

Net Margin
Bayer AG

-5.5%
Current
1%
Average
4.8%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-5.5%
=
Net Income
-2.6B
/
Revenue
46.6B

Net Margin Across Competitors

Country Company Market Cap Net
Margin
DE
Bayer AG
XETRA:BAYN
20.7B EUR
-5%
US
Eli Lilly and Co
NYSE:LLY
795.9B USD
24%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
US
Johnson & Johnson
NYSE:JNJ
379B USD
24%
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK
35%
CH
Roche Holding AG
SIX:ROG
203.3B CHF
14%
CH
Novartis AG
SIX:NOVN
183.5B CHF
23%
UK
AstraZeneca PLC
LSE:AZN
157B GBP
13%
US
Merck & Co Inc
NYSE:MRK
197.5B USD
27%
IE
Endo International PLC
LSE:0Y5F
162.4B USD
-126%
FR
Sanofi SA
PAR:SAN
113.2B EUR
13%
No Stocks Found

Bayer AG
Glance View

Economic Moat
None
Market Cap
20.7B EUR
Industry
Pharmaceuticals

Bayer AG, a German multinational behemoth, traces its roots back to 1863 in Barmen, when Friedrich Bayer and Johann Friedrich Weskott began their enterprise as a dye-making factory. Fast forward to the present day, and Bayer has evolved into a global powerhouse, seamlessly weaving through pharmaceuticals, consumer health, and agricultural science. At its core, Bayer’s business operations spin around its three main segments: Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals division is the jewel in Bayer’s crown, focusing on prescription medicines across various therapeutic areas such as oncology, cardiology, and gynecology, allowing Bayer to cater to the world's increasing demand for healthcare solutions, which not only drive patient outcomes but also account for a significant chunk of revenue. Not to be overshadowed, Bayer’s Crop Science division plays a pivotal role, emphasizing its strong commitment to sustainable agriculture. Here, the company develops seeds, traits, and crop protection products that appeal to farmers seeking to enhance yield and manage crop threats. Meanwhile, the Consumer Health division targets over-the-counter products, covering a range of everyday health issues, resonating with consumers seeking self-care solutions. Bayer’s ability to seamlessly integrate its scientific prowess into real-world applications enables the company to extract value across these sectors, creating an intricate mosaic of interdependent streams of revenue and continually reinforcing its stature as a leader in life sciences.

BAYN Intrinsic Value
113.37 EUR
Undervaluation 81%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-5.5%
=
Net Income
-2.6B
/
Revenue
46.6B
What is the Net Margin of Bayer AG?

Based on Bayer AG's most recent financial statements, the company has Net Margin of -5.5%.

Back to Top